On April 15, the annual meeting of the KTD-innov consortium took place. This meeting allows all the partners to meet in order to review the progress of the study.
The meeting was also an opportunity to exchange views with representatives of the National Research Agency (ANR), which funded the KTD-innov research project.
Several of the partners took part in this day-long meeting, including Sophie Brouard and Alexandre Loupy, the two project coordinators.
The success of this project depends in particular on the quantity and quality of data collected from volunteer patients. To date, more than 400 patients have accepted to be part of this study.
The objectives for the next steps have been set. New patients will be recruited throughout the coming year. And the analysis of the collected samples will soon begin, 50% of the samples should be analyzed by the end of 2019.
The researchers involved in the KTD-innov study will work to solve many challenges in the coming months. The data collected must be consolidated in a homogenized database that meets international security standards.
In the next few months, scientists involved in this French research project will try to identify patients at risk for allograft rejection. Bioinformatic tools will be used to analyze results from collected samples and data. A tool will then be provided to clinicians to assist the medical decision process in order to improve patients’ follow-up.
To elucidate the mechanisms of success or failure of a kidney transplant, KTD-innov collects, centralizes and analyses clinical, biological and immunological data from thousands of kidney transplant patients in France.